Invention Grant
- Patent Title: Relevance of achieved levels of markers of systemic inflammation following treatment
-
Application No.: US14886626Application Date: 2015-10-19
-
Publication No.: US11435363B2Publication Date: 2022-09-06
- Inventor: Paul M. Ridker
- Applicant: The Brigham and Women's Hospital, Inc.
- Applicant Address: US MA Boston
- Assignee: The Brigham and Women's Hospital, Inc.
- Current Assignee: The Brigham and Women's Hospital, Inc.
- Current Assignee Address: US MA Boston
- Agency: Wolf, Greenfield & Sacks, P.C.
- Main IPC: A61K31/22
- IPC: A61K31/22 ; A61K31/40 ; G01N33/68 ; G01N33/92
Abstract:
The invention involves, inter alia, the use of markers of systemic inflammation to determine whether or not an individual undergoing treatment with a cardiovascular agent to reduce the risk of a future cardiovascular event will benefit from continued treatment with the cardiovascular agent. Further, this invention describes the use of markers of systemic inflammation to evaluate the efficacy of treatment and to assist physicians in deciding on the course of a treatment in an individual at risk of future cardiovascular events.
Public/Granted literature
- US20160266146A1 RELEVANCE OF ACHIEVED LEVELS OF MARKERS OF SYSTEMIC INFLAMMATION FOLLOWING TREATMENT Public/Granted day:2016-09-15
Information query
